Median values (25th–75th percentile) of parameters examined in peripheral blood (PB) and bronchoalveolar lavage fluid (BALF) in patients with chronic progressive (P) and chronic stable (S) sarcoidosis
| Parameter | Time point | P (chronic progressive) | S | P value |
| BALF lympho (/106 L) | Baseline | 48.3 (24.5–81) | 28.3 (17.9–46.8) | 0.21 |
| BALF lympho (%) | Baseline | 33.5 (24.2–41.6) | 16.5 (13.8–33.3) | 0.069 |
| PB lympho (×109/L) | Baseline | 1.0 (0.9–1.2) | 1.4 (1.0–1.6) | 0.14 |
| 1st follow-up* | 1.1 (1.0–1.2) | 1.5 (1.2–1.6) | 0.042 | |
| 2nd follow-up* | 1.1 (0.8–1.2) | 1.4 (1.3–1.7) | 0.013 | |
| PB lympho (% of ll) | Baseline | 112 (85–133) | 140 (95.5–160) | 0.36 |
| 1st follow-up* | 106 (91–120) | 150 (120–150) | 0.042 | |
| 2nd follow-up* | 110 (73–120) | 130 (127–163) | 0.013 | |
| % Ki-67+CD4+ T cells | BALB baseine | 5.1 (4.6–6.6) | 4.3 (3.2–5.4) | 0.18 |
| PB baseline** | 4.1 (3.8–4.6) | 2.6 (2.5–3.0) | 0.002 | |
| PB 1st follow-up | 5.0 (3.8–5.7) | 3.2 (2.7–4.5) | 0.087 | |
| PB 2nd follow-up* | 5.1 (4.1–6.0) | 2.2 (1.9–3.3) | 0.033 | |
| % Ki-67+CD8+ T cells | BALF baseline | 4.0 (3.3–4.5) | 4.1 (3.4–4.8) | 0.92 |
| PB baseline | 2.9 (2.4–3.3) | 2.0 (1.4–3.2) | 0.34 | |
| PB 1st follow-up | 2.5 (1.9–3.0) | 2.0 (1.8–2.1) | 0.41 | |
| PB 2nd follow-up** | 3.2 (3.0–3.4) | 1.4 (1.3–1.6) | 0.004 | |
| % FoxP3+CD4 T cells | BALF baseline | 5.4 (4.1–6.1) | 4.6 (3.3–5.0) | 0.30 |
| PB baseline | 6.4 (4.6–7.7) | 2.4 (2.1–5.3) | 0.057 | |
| PB 1st follow-up | 4.3 (4.2–5.7) | 3.4 (2.0–5.4) | 0.29 | |
| PB 2nd follow-up | 5.2 (4.0–7.8) | 3.7 (3.1–4.9) | 0.083 |
% of ll denotes percent of lower limit for normal PB lymphocytes value.
*p<0.05, **p<0.01.
lympho, lymphocytes.